Globally, the need is greatest in resource-restricted countries with reduced HIV recognition and deficiency of education and learning about cure and avoidance solutions. Since 2006, Gilead has entered into voluntary licensing agreements with generic makers in reduced- and middle-money countries that grant them the rights to generate and promote superior-quality, https://www.directivepublications.org/journal-of-hiv-aids-research/